Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
Holding CELC?
Track your performance easily
CELC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.51 - $22.19
Previous Close$12.78
Volume205.51K
Average Volume (3M)285.87K
Market Cap
$463.01M
Enterprise Value$296.14M
Total Cash (Recent Filing)$264.06M
Total Debt (Recent Filing)$97.19M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Mar 20, 2025EPS Estimate
-$0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.61
Shares Outstanding37,129,556
10 Day Avg. Volume412,722
30 Day Avg. Volume285,867
Standard Deviation0.25
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.17
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.46
Forecast
1Y Price Target
$29.00Price Target Upside127.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Celcuity News
PremiumCompany Announcements
Celcuity Inc. Reports Q3 Progress and Financials
Bulls Say, Bears Say
Bulls Say
Clinical TrialsGiven the favorable comparison with previous studies, VIKTORIA-1 is expected to deliver a positive data readout.
Drug DevelopmentGedatolisib aims to induce stronger anti-tumor activity than either the approved PI3K inhibitor from Novartis, Piqray (alpelisib), and mTOR inhibitor, Afinitor (everolimus), for advanced ER+ breast cancer patients, while at the same time minimizing/avoiding the systemic toxicities that have plagued agents targeting the PI3K/AKT/mTOR pathway.
Financial PerformanceCash and cash equivalents of $264M are believed to be sufficient to fund operations for the foreseeable future.
Bears Say
Clinical TrialsThe readout for the highly anticipated PIK3CA WT cohort in the Phase 3 VIKTORIA-1 trial in 2L HR +/HER2- advanced breast cancer has been delayed.
Financial PerformanceThe company reported no revenues, and a net loss of $0.70 per diluted share, compared to consensus estimate of no revenues and a net loss of $0.65 per diluted share.
Investor ConcernsThe recent announcement of a slight delay in the WT readout has caused concerns among some investors that the control arm may be overperforming relative to expectations.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $11.51 and its highest was $22.19 in the past 12 months.
What is Celcuity’s market cap?
Currently, no data Available
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is Mar 20, 2025 which is in 118 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on Nov 14, 2024. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.653 by -$0.047.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -$0.71.
How many shares outstanding does Celcuity have?
Celcuity has 37,129,555 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.653. Following the earnings report the stock price went down -10.276%.
Which hedge fund is a major shareholder of Celcuity?
Among the largest hedge funds holding Celcuity’s share is Perceptive Advisors LLC. It holds Celcuity’s shares valued at 35M.
---
Celcuity Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (127.81% Upside)
$29.00 (127.81% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 183.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.29%
12-Months-Change
Fundamentals
Return on Equity
-77.47%
Trailing 12-Months
Asset Growth
91.76%
Trailing 12-Months
Company Description
Celcuity
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded in January 2012 by Brian Sullivan and Lance Laing and is headquartered in Minneapolis, MN.
---
CELC Earnings Call
Q3 2024
0:00 / 0:00
---
CELC Stock 12 Month Forecast
Average Price Target
$29.00
▲(127.81% Upside)
Technical Analysis
Ocular Therapeutix
―
Kala Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Karyopharm Therapeutics
―
Best Analysts Covering CELC
1 Year
---